Madrid, Spain, 13 June 2013: Data presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, show that up to one-third of rheumatoid arthritis (RA) patients discontinue or change therapy within the first year of treatment.
Loss of efficacy was the most common reason given (35.8%), followed by safety (20.1%), physician or patient preference (27.8% and 17.9%, respectively) and access to treatment (9.0%). Rates and rationale for treatment discontinuation were similar for both tumour necrosis factor inhibitors (TNFi) and non-TNFi biologics.
RA is a chronic autoimmune disease that principally attacks flexible joints. Affecting approximately 1 in 100 people worldwide, RA can cause pain, stiffness, progressive joint destruction and deformity, and reduce physical function, quality of life and life expectancy. At least 50% of RA patients in developed countries are unable to hold down a full-time job within 10 years of onset.2
Lead author of the study, Vibeke Strand, MD, Clinical Professor, Stanford University School of Medicine, Portola Valley, California, USA, said, "RA is a progressive disease which, if left untreated, can significantly and permanently reduce joint function, patient mobility and quality of life. Studies have shown that patients sustain maximum benefit from RA treatment in the first two years3 yet our data highlight significant discontinuation rates during this time period."
Dr. Strand continued, "While there is no cure for RA, initiating treatment early and improving adherence can enable patients to lead active and productive lives. These data are derived from a US experience, which is associated with a significantly greater prevalence of biologic utilisation than is typically seen elsewhere. The results may, therefore, be different in societies with less prevalent utilization of these agents."
The study was designed to examine initiation of biologic therapies within the US
|Contact: EULAR Press Office|
European League Against Rheumatism